# A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

> **NCT06259981** · PHASE2 · COMPLETED · sponsor: **Glyscend, Inc.** · enrollment: 75 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** GLY-200
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06259981
- **Lead sponsor:** Glyscend, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-20
- **Primary completion:** 2024-10-23
- **Final completion:** 2024-10-23
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2025-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06259981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06259981, "A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06259981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*